MYGN (Myriad Genetics Inc) Stock Analysis - Hedge Fund Holdings
Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of May 21, 2026, MYGN trades at $3.81 with a market cap of $344.74M and a P/E ratio of -0.86. MYGN moved +6.76% today. Year to date, MYGN is -37.95%; over the trailing twelve months it is -14.38%. Its 52-week range spans $3.53 to $27.55. Analyst consensus is neutral with an average price target of $7.20. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns MYGN stock?
Hedge funds tracked by Rallies that own MYGN include Glenview Capital and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Myriad Genetics Inc.
MYGN Key Metrics
Key financial metrics for MYGN
Metric
Value
Price
$3.81
Market Cap
$344.74M
P/E Ratio
-0.86
EPS
$-4.29
Dividend Yield
0.00%
52-Week High
$27.55
52-Week Low
$3.53
Volume
0
Avg Volume
0
Revenue (TTM)
$829.00M
Net Income
$-399.90M
Gross Margin
69.96%
Top Hedge Funds Holding MYGN
Glenview Capital holds 5.41M shares of MYGN, changed +17.97% as of Mar 31, 2026.
Centerbook Partners holds 10.85K shares of MYGN, changed +0.00% as of Sep 30, 2024.
Hedge funds tracked by Rallies that own MYGN include Glenview Capital and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Myriad Genetics Inc.
Does Rallies show 13F holders for MYGN?
Yes. Rallies tracks hedge fund and 13F ownership data for MYGN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MYGN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for MYGN. It does not provide personalized investment advice.
